SMO Antibody - #DF5152

Fig. S5 |a Western blottingting showing the most pronounced effect of Smo silencing in the shSmo #2 group in BGC823MCAs and SGC7901MCAs.

FIGURE 5 |Curcumin suppresses the TGF-β1-activated Hedgehog signaling in HIBECs. (a) Quantitative analysis of Shh, Gli1, Smo, Ptch-1, and Sufu protein expression.

Fig. 4. Gprasp2-KO induced apoptosis in HEI-OC1 cells by inhibiting Hh signaling pathway. (A) Flow cytometry assay of Gprasp2-WT/KO HEI-OC1 cells with no PUR-treatments (WT, KO) or with PUR-treatments (WT þ PUR, KO þ PUR). (B) Statistics of apoptotic cells in WT/KO/WT þ PUR/KO þ PUR groups (n ¼ 3, *p < 0.05). (C) Western blot assay of the key molecules of apoptosis (Bcl2, Bax, Casepase3, cleaved-Casepase3) and Hh signaling pathway (Smo, Gli1, Gli2) in WT/KO/WT þ PUR/KO þ PUR groups. (D) Statistics of the key molecules of apoptosis (Bcl2, Bax, Casepase3, cleaved-Casepase3) and Hh signaling pathway (Smo, Gli1, Gli2) in WT/KO/WT þ PUR/KO þ PUR groups (n ¼ 3; *p < 0.05).

Figure 2 Ubenimex blocked Hh signaling by targeting CD13 in liver cancer cell lines. (A-C) Western blot analysis of the protein expression levels of CD13, PTCH1, GLI1, SMO, and SHH in Huh7, HepG2, and PLC/PRF/5 cells treated with 0.05 or 0.1 mg/mL ubenimex. Densitometry analysis was used to normalize the expression levels of the proteins to those of β-actin; mean ± SD is indicative of three independent experiments (*, P